Medication Management and Culture of Safety (MM)
|ClinicalTrials.gov Identifier: NCT01247454|
Recruitment Status : Completed
First Posted : November 24, 2010
Last Update Posted : December 6, 2016
There will be no significant decrease in the use of low dose acetylsalicylic acid (ASA) therapy for primary prevention across the three intervention arms from baseline to completion of the project.
There will be no significant differences in the percentage of patients with diabetes mellitus greater than 44 years of age on low dose ASA therapy for primary prevention across the three arms of the study using repeated measures from baseline to completion of the project.
|Condition or disease||Intervention/treatment|
|Cardiovascular Disease||Behavioral: academic detailing Behavioral: Electronic Health Record (EHR) prompt Behavioral: EHR prompt and patient prompt|
We will assess the current use of aspirin therapy for primary and secondary cardiovascular disease prevention in six general internal medicine and family medicine clinics within the University of Colorado Hospital system using electronic health record data.
We will develop messages concerning the appropriate use of aspirin for cardiovascular disease prevention for academic detailing to clinicians, a point of care (EHR) decision support aid for clinicians, and a short information sheet (generated by a CDS) for patients.
We will test the effectiveness of interventions to improve the evidence-based use of aspirin for primary and secondary prevention of cardiovascular disease using a randomized trial in the six University of Colorado Hospital primary care practices studied. The three intervention arms will include:
1.academic detailing and cessation of the primary prevention reminder within the point of care clinical decision support system (EHR/CDS) only 2. academic detailing with an EHR/CDS message asking clinicians to consider stopping aspirin therapy for primary prevention embedded in the point of care clinical decision support system 3. academic detailing with the EHR/CDS point of care message for clinicians in the second paragraph above, and a short information sheet to be given to patients prior to a visit to ask them to check with their provider concerning their use of aspirin for primary prevention
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||7000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Risk Informed Intervention Development and Implementation of Safe Ambulatory Care|
|Study Start Date :||July 2009|
|Primary Completion Date :||December 2009|
|Study Completion Date :||September 2010|
All arms will receive this intervention
Behavioral: academic detailing
EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
Experimental: Electronic Health Record (EHR) prompt
One intervention arm will receive the EHR prompt along with the academic detailing
Behavioral: Electronic Health Record (EHR) prompt
EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
Experimental: EHR prompt and patient prompt
The final arm will receive this combined intervention plus the academic detailing
Behavioral: EHR prompt and patient prompt
EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
- Using a baseline cohort design is there any difference in the number of patients on ASA based on EHR medication lists for apparent primary prevention among the three groups after 24 months. [ Time Frame: 12 months later ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01247454
|United States, Colorado|
|University Hospital Clinics|
|Denver, Colorado, United States, 80045|
|Study Director:||Wilson Pace, MD||University of Colorado Department of Family Medicine|